Adynxx, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2019
November 14, 2019 at 04:30 pm IST
Share
Adynxx, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2019. For the quarter, the company reported loss from operations of $1,672,000 against $1,334,000 a year ago. Loss from continuing operations was $1,895,000 against $1,505,000 a year ago. Net loss was $1,895,000 against $1,505,000 a year ago. Net loss per basic share was $0.33 against $2.14 a year ago.
For the nine months, the company reported loss from operations of $6,017,000 against $3,895,000 a year ago. Loss from continuing operations was $8,975,000 against $4,451,000 a year ago. Net loss was $9,033,000 against $4,451,000 a year ago. Net loss per basic share was $2.58 against $6.34 a year ago.
Adynxx, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of a new class of therapeutics called transcription factor decoys and bringing to market disease-modifying products to address unmet needs in the treatment of pain and inflammation. The Company has leveraged its AYX platform of proprietary transcription factor decoys to identify and develop product candidates designed to modify the course of pain. Its product pipeline includes Brivoligide for postoperative pain and AYX2 for chronic pain. Brivoligide is a transcription factor decoy specifically designed to inhibit the function of transcription factor Early Growth Response 1 (EGR1), in the dorsal root ganglia (DRG), and spinal cord when administered at the time of surgery. Its second product candidate, AYX2, is a transcription factor decoy targeting the activity of specific members of the KLF family of transcription factors, including KLF6, KLF9 and KLF15.
ADYNXX, INC. 